Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.56 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.52 |
| ▸ | BCL2 | P10415 | 1/20 | 0.48 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | CTRC | Q99895 | 1/20 | 0.42 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | DRD1 | P21728 | 1/20 | 0.41 |
| ▸ | DRD3 | P35462 | 1/20 | 0.41 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9463665 | 0.88 | TSHR (0.52) | HTR2ATRPA1ALDH1A1TSHRCALM1 | |
| SCHEMBL972711 | 0.87 | CALM1 (0.69) | HTR2ACALM1BCL2BCL2L1L3MBTL1 | |
| SCHEMBL11631513 | 0.82 | MEN1 (0.43) | HTR2AHPGDMEN1KMT2AKEAP1 | |
| SCHEMBL9669021 | 0.82 | HTR2A (0.39) | HTR2ATRPA1ALDH1A1TSHRCALM1 | |
| SCHEMBL5156201 | 0.82 | SLC5A1 (0.41) | HTR2AALDH1A1KEAP1 | |
| SCHEMBL5973034 | 0.81 | HTR2A (0.63) | HTR2ATRPA1ALDH1A1TSHRCALM1 | |
| SCHEMBL29382225 | 0.81 | TSHR (0.50) | TRPA1ALDH1A1TSHRTDP1HIF1A | |
| SCHEMBL28289 | 0.81 | TSHR (0.50) | TRPA1ALDH1A1TSHRTDP1HIF1A | |
| SCHEMBL4324784 | 0.81 | TRPA1 (0.44) | HTR2ATRPA1ALDH1A1TSHRCALM1 | |
| SCHEMBL7083714 | 0.79 | BCL2 (0.48) | HTR2ATRPA1ALDH1A1TSHRCALM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0150826-A2 | Difficult flammable biodegradable functional fluid | HYDROCOR FORSCHUNGS- UND ANALYTIK GMBH (DE) | 1985-08-07 | — | — | EP | claimed |
| WO-1985003306-A1 | HARDLY INFLAMMABLE, BIOLOGICALLY DEGRADABLE FUNCTIONAL LIQUID | HYDROCOR FORSCHUNGS-UND ANALYTIK GMBH (DE) | 1985-08-01 | — | — | WO | claimed |
| US-20240002344-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR HISTONE LYSINE DEMETHYLASE INHIBITION | FIBROGEN, INC. | 2024-01-04 | — | — | US | disclosed |
| EP-4204400-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR HISTONE LYSINE DEMETHYLASE INHIBITION | Fibrogen, Inc. (US) | 2023-07-05 | — | — | EP | disclosed |
| CN-116348450-A | Compounds, compositions and methods for histone lysine demethylase inhibition | 菲布罗根有限公司 | 2023-06-27 | — | — | CN | disclosed |
| WO-2022047230-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR HISTONE LYSINE DEMETHYLASE INHIBITION | FIBROGEN, INC. (US) | 2022-03-03 | — | — | WO | disclosed |
| US-9149462-B2 | Pyrazole compounds acting against allergic, inflammatory and immune disorders | GLAXO GROUP LIMITED (GB) | 2015-10-06 | — | — | US | disclosed |
| US-9149462-B2 | Pyrazole compounds acting against allergic, inflammatory and immune disorders | GLAXO GROUP LIMITED (GB) | 2015-10-06 | — | — | US | disclosed |
| US-9149462-B2 | Pyrazole compounds acting against allergic, inflammatory and immune disorders | GLAXO GROUP LIMITED (GB) | 2015-10-06 | — | — | US | disclosed |
| EP-1559422-B1 | RECEPTOR FUNCTION CONTROLLING AGENT | TAKEDA PHARMACEUTICAL (JP) | 2014-04-30 | — | — | EP | disclosed |
| EP-2635124-A1 | ALKYLSULFINYL-SUBSTITUTED THIAZOLIDE COMPOUNDS | Romark Laboratories, L.C. (US) | 2013-09-11 | — | — | EP | disclosed |
| EP-0752421-A1 | Ortho-substituted aromatic compounds, containing three (het)aryl moieties, their preparation and their use as prostaglandin E2-(PGE2)-antagonists | ZENECA LIMITED (GB) | 1997-01-08 | — | — | EP | disclosed |
| US-5534532-A | ANTICHOLESTEROL AGENTS, SQUALENE SYNTHASE INHIBITOR | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1996-07-09 | — | — | US | disclosed |
| US-5494918-A | ANTICHOLESTEROL AGENTS | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1996-02-27 | — | — | US | disclosed |
| US-5455260-A | Anticholesterol agents; reduction of serum cholesterol without reducing mevalonic metabolite synthesis; side effect | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1995-10-03 | — | — | US | disclosed |
| US-5395846-A | Amino Bi- and tri-carbocyclic aklane bis-aryl squalene synthase inhibitors | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1995-03-07 | — | — | US | disclosed |
| US-5385912-A | Hypocholesterolemic or hypolipidemic agents | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1995-01-31 | — | — | US | disclosed |
| WO-1995000146-A1 | AMINO BI- AND TRI-CARBOCYCLIC ALKANE BIS-ARYL SQUALENE SYNTHASE INHIBITORS | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1995-01-05 | — | — | WO | disclosed |
| WO-1994027601-A1 | ALIPHATIC AMINO BIS-ARYL SQUALENE SYNTHASE INHIBITORS | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1994-12-08 | — | — | WO | disclosed |
| WO-1992015579-A1 | MULTICYCLIC TERTIARY AMINE POLYAROMATIC SQUALENE SYNTHETASE INHIBITORS | RHONE-POULENC RORER INTERNATIONAL (HOLDINGS) INC. (US) | 1992-09-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240002344-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR HISTONE LYSINE DEMETHYLASE INHIBITION | KDM5C, KDM5B, KDM5A | HTR2A 3818/4885TRPA1 4860/4885ALDH1A1 2449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.